Targeting the endocannabinoid system as a potential anticancer approach

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• The endocannabinoid system (ECS) is a target for cancer therapeutics.
• The ECS includes cannabinoid receptors (CB1, CB2), endocannabinoids (anandamide, 2-arachidonoylglycerol), and related molecules.
• Emerging research highlights an 'extended' ECS with broader implications for disease.

Purpose of the Study:

• To review the antitumorigenic effects of modulating the extended endocannabinoid network.
• To explore novel therapeutic targets within the broader ECS for cancer treatment.

Main Methods:

• Literature review of studies investigating the endocannabinoid system and cancer.
• Analysis of research on fatty acid derivatives, receptors, enzymes, and lipid transporters involved in the extended ECS.
• Examination of antitumoral activities associated with modulating these components.

Main Results:

• Fatty acids acting on cannabinoid receptors (e.g., noladin ether, N-arachidonoyldopamine) show anticancer potential.
• Endocannabinoid-like substances (e.g., N-palmitoylethanolamine, N-oleoylethanolamine) exhibit anticancerogenic properties.
• Enzymes (e.g., fatty acid amide hydrolase, monoacylglycerol lipase) and receptors (e.g., TRP, PPARs) within the extended ECS are potential targets for antitumoral activity.

Conclusions:

• The extended endocannabinoid network offers promising targets for novel anticancer drug development.
• Modulation of this expanded system presents a multifaceted approach to cancer therapy.